Lynn Rothman - Penumbra Executive Vice President, Chief Business Officer
| PEN Stock | USD 356.00 0.99 0.28% |
President
Ms. Lynn Rothman serves as Executive Vice President, Chief Business Officer of Penumbra, Inc. She joined Penumbra in 2007. She has served as Executive Vice President and Chief Business Officer since January 2015 as Chief Financial Officer from March 2009 to January 2015 as Vice President, Administration from January 2009 to March 2009, and as Human Resources Manager from 2007 to January 2009. Ms. Rothman joined Penumbra with over 20 years of experience in finance and marketing of medical and emerging growth companies since 2015.
| Age | 63 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Address | One Penumbra Place, Alameda, CA, United States, 94502 |
| Phone | 510 748 3200 |
| Web | https://www.penumbrainc.com |
Penumbra Management Efficiency
The company has Return on Asset of 0.067 % which means that on every $100 spent on assets, it made $0.067 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1332 %, implying that it generated $0.1332 on every 100 dollars invested. Penumbra's management efficiency ratios could be used to measure how well Penumbra manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Penumbra's Return On Capital Employed is very stable compared to the past year. As of the 4th of February 2026, Return On Equity is likely to grow to 0.01, while Return On Tangible Assets are likely to drop 0.01. At this time, Penumbra's Total Assets are very stable compared to the past year. As of the 4th of February 2026, Non Current Assets Total is likely to grow to about 702.8 M, while Other Current Assets are likely to drop about 21.9 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Brik Eyre | Baxter International | 54 | |
| Stuart Hockridge | Align Technology | 54 | |
| Annette Tumolo | Bio Rad Laboratories | 65 | |
| Zelko Relic | Align Technology | 61 | |
| Brian Stevens | Baxter International | 49 | |
| Clare Trachtman | Baxter International | N/A | |
| Jim Gustafson | DaVita HealthCare Partners | N/A | |
| Cristiano Franzi | Baxter International | 61 | |
| Jonathan DiVincenzo | Bio Rad Laboratories | 60 | |
| Giovanni Magni | Bio Rad Laboratories | 63 | |
| Michael Ettinger | Henry Schein | 65 | |
| Joseph LaPlume | Charles River Laboratories | 50 | |
| Sean Martin | Baxter International | 58 | |
| Atul Mathur | DaVita HealthCare Partners | N/A | |
| Christopher Pendergast | Henry Schein | 63 | |
| Scott Pleau | Baxter International | 52 | |
| Michael Crowley | Bio Rad Laboratories | 64 | |
| Ilan Daskal | Bio Rad Laboratories | 58 | |
| LeAnne Zumwalt | DaVita HealthCare Partners | 60 | |
| Brett Murphy | Globus Medical | 59 | |
| William Barbo | Charles River Laboratories | 64 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.067 |
Penumbra Leadership Team
Elected by the shareholders, the Penumbra's board of directors comprises two types of representatives: Penumbra inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Penumbra. The board's role is to monitor Penumbra's management team and ensure that shareholders' interests are well served. Penumbra's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Penumbra's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ben Tompkins, Executive Development | ||
| Surbhi Sarna, Independent Director | ||
| Bridget ORourke, Independent Director | ||
| Adam Elsesser, Chairman of the Board, Chief Executive Officer | ||
| James Pray, President International | ||
| Shruthi Narayan, Executive Interventional | ||
| Gita Barry, President Healthcare | ||
| Holly Sit, Director Development | ||
| Lynn Rothman, Executive Vice President, Chief Business Officer | ||
| Arani MD, CoFounder Director | ||
| Pankaj Tiwari, Executive Officer | ||
| Harpreet Grewal, Independent Director | ||
| Maggie Yuen, Chief Financial Officer | ||
| Jee HamlynHarris, Investor Officer | ||
| Don Kassing, Presiding Independent Director | ||
| Adam JD, Chairman, CoFounder | ||
| Ben Sorci, Executive Operations | ||
| Lambert Shiu, Chief Accounting Officer | ||
| Johanna Roberts, Executive Vice President General Counsel, Secretary | ||
| MD FSIR, Chief Officer | ||
| Jason Mills, Executive Strategy | ||
| Thomas Wilder, Independent Director | ||
| Sandra Lesenfants, President Interventional | ||
| Arani Bose, Executive Director and Chief Innovator | ||
| Johanna JD, General VP | ||
| Janet Leeds, Lead Independent Director | ||
| Steve Chen, Director Management |
Penumbra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Penumbra a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.067 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 13.75 B | ||||
| Shares Outstanding | 39.23 M | ||||
| Shares Owned By Insiders | 3.72 % | ||||
| Shares Owned By Institutions | 97.76 % | ||||
| Number Of Shares Shorted | 1.72 M | ||||
| Price To Earning | 191.13 X |
Pair Trading with Penumbra
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Penumbra position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Penumbra will appreciate offsetting losses from the drop in the long position's value.Moving against Penumbra Stock
| 0.86 | OTC | Ocumetics Technology Corp | PairCorr |
| 0.82 | AHC | Austco Healthcare | PairCorr |
| 0.77 | IHC | Inspiration Healthcare | PairCorr |
| 0.72 | IVF | INVO Fertility Symbol Change | PairCorr |
| 0.7 | RHT | Resonance Health | PairCorr |
The ability to find closely correlated positions to Penumbra could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Penumbra when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Penumbra - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Penumbra to buy it.
The correlation of Penumbra is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Penumbra moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Penumbra moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Penumbra can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Penumbra. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. To learn how to invest in Penumbra Stock, please use our How to Invest in Penumbra guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Will Health Care Equipment & Supplies sector continue expanding? Could Penumbra diversify its offerings? Factors like these will boost the valuation of Penumbra. Anticipated expansion of Penumbra directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Penumbra data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.56 | Earnings Share 4.18 | Revenue Per Share | Quarterly Revenue Growth 0.178 | Return On Assets |
Investors evaluate Penumbra using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Penumbra's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Penumbra's market price to deviate significantly from intrinsic value.
It's important to distinguish between Penumbra's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Penumbra should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Penumbra's market price signifies the transaction level at which participants voluntarily complete trades.